Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 678 across all filing types
Latest filing 2024-05-09 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification about an upcoming Earnings Conference Call scheduled for May 22, 2024, to discuss the company's financial performance for the quarter and fiscal year ended March 31, 2024. It includes details about the call, dial-in information, and mentions that the transcript and audio recording will be made available on the company's website after the call. The document does not contain actual financial data or results but is an announcement of the event where such information will be discussed. According to the classification rules, announcements about earnings calls are classified as Call Transcript (CT) only if they contain the full transcript. Since this document is only an announcement of the call, it does not qualify as a transcript. It is also not an Earnings Release (ER) because it does not provide financial highlights or results. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the earnings call event.
2024-05-09 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is a formal notification from Gland Pharma Limited to stock exchanges about an upcoming Board Meeting scheduled for May 22, 2024. The agenda includes consideration and approval of audited financial results for the quarter and fiscal year ended March 31, 2024, and recommendation of a final dividend. It also mentions the reopening of the trading window and an earnings call scheduled for the same day. The document is an announcement of a future event (Board Meeting) and related activities, not the actual financial results or reports themselves. The length is short (1991 characters), and it serves as an intimation under SEBI regulations. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the actual financial data or report.
2024-05-09 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Gland Pharma has received US FDA approval for a specific pharmaceutical product (Edaravone Injection). It is addressed to stock exchanges and references regulatory compliance under SEBI Listing Obligations. The content focuses on the approval news and product details, with no financial statements, management discussion, or detailed report data. The document length is 4135 characters, which is relatively short and typical for an announcement rather than a full report. There is no indication that this is a full financial report, earnings release, or regulatory filing beyond the announcement itself. Therefore, this document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a material event (FDA approval) that does not fit into other specific categories like earnings, capital updates, or management changes.
2024-05-07 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Gland Pharma has received US FDA approval for a specific pharmaceutical product (Plerixafor Injection). It is addressed to stock exchanges and references regulatory compliance under SEBI Listing Obligations. The content focuses on the approval news and product details, with no financial statements or detailed financial performance data. The document length is 4137 characters, which is relatively short and typical for an announcement rather than a full report. There is no indication that this is an earnings release, annual report, or any detailed financial filing. It is clearly an announcement of a regulatory approval event, which fits best under the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-05-07 English
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal announcement dated April 29, 2024, addressed to stock exchanges, informing about the appointment of a new Chief Operating Officer and Senior Management Personnel. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosures about changes in the board or senior management. The content includes detailed personal and professional information about the appointee but does not contain financial data, earnings, or report content. The document is not a full report but an announcement of a management change.
2024-04-29 English
Outcome of Board Meeting
Board/Management Information Classification · 100% confidence The document is a formal announcement from the company to stock exchanges regarding the outcome of a board meeting. It specifically informs about the appointment of a new Chief Operating Officer and Senior Management Personnel, including detailed background information about the appointee. The document references compliance with SEBI regulations related to disclosure of material events. There is no financial data, earnings information, or report attached or referenced as being published. The content focuses on management changes, which aligns with announcements about changes in the company's board or senior management. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 3803 characters, which is relatively short and consistent with an announcement rather than a full report.
2024-04-29 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.